B+
Bull case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
STRO
Sutro BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
STRO-004 has produced early clinical responses in heavily pretreated patients, with rapid enrollment, mostly low-grade adverse events, predictable PK, and only 6% discontinuation due to adverse events. STRO-006 and partnered Astellas programs add pipeline optionality, while management reported $164.3 million of cash, cash equivalents, and marketable securities expected to fund operations into at least Q2 2028 [#SEC-8K-2026-08-12].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -11.4.
What can break
Dose-limiting toxicities occurred at 5 mg/kg, with target-related toxicity and dose reduction; grade 3 anemia occurred in 14% of patients [#SEC-8K-2026-08-12].
Momentum
5
Value
41
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.00 · Bull $40.00 · Bear $11.00Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $47.23
Why
Momentum5 · Δ7d -0.4
Value41 · Δ7d 0.0
Sentiment87 · Δ7d -11.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -11.4.
Contradictions & invalidation
- • Dose-limiting toxicities occurred at 5 mg/kg, with target-related toxicity and dose reduction; grade 3 anemia occurred in 14% of patients [#SEC-8K-2026-08-12].
- • Management's stated cash runway reduces near-term financing pressure but does not remove clinical execution or future capital-needs risk.
- • The lead asset remains in dose escalation with no defined maximum tolerated dose; dose-limiting toxicities occurred at 5 mg/kg, dose reduction was required, and reported responses include unconfirmed partial responses.
Catalyst clock
2026-12-02
STRO-006 clinic entry
Lead driver: Sentiment · See AI snapshot
Momentum
5
9% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-7.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
87
62% active weight
Current posture
7d trendSoftening
Δ7d
-11.4
Δ21d
-8.8
Why this grade
Composite grade B. Momentum 4.6 / Value 41.2 / Sentiment 87.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$369.43M
Beta
1.55
Shares Out
16.58M
P/E (TTM) · Derived
-1.0
P/S (TTM)
0.88
P/FCF (TTM) · Derived
-1.69
Rev YoY
-84.6%
EPS YoY
+71.0%
Gross Margin
+86.7%
Op Margin
-288.5%
Net Debt
$93.78M
Current Ratio
3.32
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data